Epirubicin
Invasive Lobular Breast Carcinoma
Auxilio Mutuo Cancer CenterUNKNOWNPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
11 Active assets in the Invasive Lobular Breast Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fulvestrant M.D. Anderson Cancer Center | Phase 3 | BB |
Anastrozole Alliance for Clinical Trials in Oncology | Phase 3 | B |
Fes F-18 Asan Medical Center | Phase 2 | B |
FAPI74 Randy Yeh | Phase 2 | CCC |
Trastuzumab Auxilio Mutuo Cancer Center | Phase 2 | CCC |
View all 21 →
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →